FROM THE EDITOR
The skinny-label fight is over.
On June 4, the Supreme Court ruled 9-0 that Amarin had not plausibly alleged that Hikma actively induced infringement of its cardiovascular patents. On October 21, Amarin dropped the suit. The case that produced the Federal Circuit’s most aggressive theory of induced infringement — the one that made every generic filer with a section viii carve-out reconsider its press release strategy — ended at the pleading stage.
The lesson is not that skinny labels are safe. The lesson is that the pleading standard is the first battlefield, and that what a generic company says about its product matters as much as what its label omits. Justice Jackson’s opinion drew a line the patent bar will spend years mapping.
This issue walks through that line and what it means for the CLO on both sides of a patent expiry.
Sources: Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., No. 24-889 (U.S. June 4, 2026); law firm analysis from Choate Hall & Stewart, Proskauer, Nixon Peabody, and Foley Hoag; Law360 reporting on the October 21 dismissal (terms paywalled). Nothing here is legal advice.
— John LaRocca
THE CASE IN 60 SECONDS
Amarin sells Vascepa, an omega-3 drug approved to lower triglycerides in adults with severe hypertriglyceridemia — the unpatented use — and to reduce cardiovascular risk in adults already on a statin — the patented use. Hikma filed for a generic with a section viii carve-out: it adopted the unpatented triglyceride indication and carved the CV indication out of its label entirely.
Amarin sued under 35 U.S.C. § 271(b), arguing that Hikma induced physicians to prescribe its generic for the patented CV use. Amarin’s theory rested on four categories of conduct: Hikma described its product as “generic Vascepa” in press releases; it cited Vascepa’s total sales figures (the bulk of which came from the CV indication) in investor materials; its label retained clinical study information about CV outcomes; and its website described the product in broad therapeutic terms without restricting it to the severe hypertriglyceridemia indication.
The Federal Circuit held those allegations were enough to survive a motion to dismiss. The Supreme Court disagreed, 9-0.
WHAT THE COURT HELD
Justice Jackson’s opinion turned on the word “active.” Section 271(b) requires that the defendant actively induce infringement. That requires an affirmative act, not an omission, not silence, not standard industry language that an observer might interpret as encouragement.
The Court structured the analysis around what a complaint must plausibly allege under Twombly and Iqbal. For inducement, the plaintiff must allege facts making it plausible (not merely possible) that the defendant took active steps to encourage the infringing use.
Amarin’s allegations failed that test on each count:
“Generic Vascepa.” Calling a product a generic equivalent of the branded drug is standard industry practice, with an obvious alternative explanation: the company is accurately describing its regulatory status. That obvious alternative defeats the inducement inference.
Sales figures in investor materials. Citing total Vascepa sales as a market reference does not plausibly allege that Hikma was encouraging doctors to prescribe for the CV indication. The speculative chain in which the investor reads it, infers the CV use, eventually influences a prescription, is possible but not plausible.
Retained clinical study information. Hikma’s label kept CV outcomes data because FDA regulations require the generic label to mirror the brand label except for the carved-out use. Following a statutory obligation is not an active step toward infringement.
Broad website language. A category description without specific instruction to prescribe for the patented indication is too vague to constitute active encouragement.
The Court added a note on the structure of the analysis: the question is not whether a physician could read these materials as instructions to infringe. The question is whether Hikma actively encouraged the infringing use. Those are different questions. Reversing them was the Federal Circuit’s error.
WHAT “ACTIVE” MEANS NOW
The Court did not hold that implicit inducement is impossible. It said inducement need not be express — a defendant can induce through implicit encouragement — but that encouragement must be “affirmative” and “clear to the relevant audience.”
That standard has two practical consequences.
First, omissions do not qualify. A generic company that carves out a patented use and says nothing about it has not induced infringement. There is no obligation to affirmatively disclaim the carved-out indication; at least not at the pleading stage.
Second, the content of affirmative communications still matters. The Court “decline[d] to put generic manufacturers between a rock and a hard place,” but it did not issue a blank check. A press release that explicitly promotes the carved-out use, a sales force trained on the patented indication’s patient population, a website that cross-references the patented benefit are a different set of facts. The case ended because Amarin’s complaint did not allege them. The holding does not say they would be insufficient if properly alleged.
THE SECTION VIII PATHWAY AFTER JUNE 4
The section viii carve-out is the route a generic filer takes when it acknowledges that a patent covers a use, carves that use out of its label, and files its ANDA relying only on the unpatented indication. The carve-out tells FDA: I am not seeking approval for the patented use, so I am not required to certify invalidity or non-infringement.
The Federal Circuit’s pre-Hikma framework — particularly GlaxoSmithKline v. Teva — had made the section viii pathway precarious. Under that framework, ordinary commercial conduct could survive a motion to dismiss and proceed to discovery. Discovery cost was itself a deterrent to filing.
Hikma changes the calculus at the pleading stage. A complaint must allege specific facts showing affirmative encouragement of the patented use. Standard commercial language, investor disclosures, and label compliance do not get the brand plaintiff to discovery.
For the brand CLO: the first question after a section viii filing is not whether the generic’s label omits the patented use. It is whether the generic’s pre-launch and post-launch communications contain affirmative, specific encouragement of the carved-out indication. That investigation has to start before the generic launches — after launch, the communications are already in the market.
THE LIFE SCIENCES CLO AND THE PATENT CLIFF
The Hikma opinion matters most to the CLO at the company staring at a patent cliff — the period in which a key patent expires, an ANDA filer emerges, and commercial erosion begins.
The CLO’s window between a section viii filing and generic launch is typically short. Five questions to answer in that window:
What uses are patented, and which ones drive active prescriptions? The patent-indication overlap is not always obvious from the claims. A patented method claim covering cardiovascular risk reduction can cover a population that also uses the drug for severe hypertriglyceridemia.
Does the ANDA filer’s proposed label retain clinical study data or cross-references that could constitute implicit encouragement? The Hikma holding was that statutory compliance explained the retention. If the label includes data beyond what FDA’s mirroring requirement demands, that is a different question.
What is the ANDA filer saying publicly about the product’s market opportunity? Investor presentations, earnings call transcripts, and analyst day slides are in the public record from the moment of filing. Pull them before the litigation team drafts the complaint.
Is the sales force trained on the carved-out indication? Training materials are discoverable and are the most direct evidence of active inducement. A Hikma-compliant complaint will need them.
If we proceed to litigation, what specific facts support the inducement theory? Post-Hikma, the complaint needs to identify specific communications that constitute affirmative encouragement. Market share and commercial ambiguity are not enough. Know this before filing.
BOX: THE LAUNCH COMMUNICATION CHECKLIST
For CLOs overseeing a generic or biosimilar launch with a section viii carve-out
The Hikma standard protects ordinary commercial language. These six items are where the line is:
Press releases. Does any release describe the product’s market opportunity by reference to a use the label has carved out? Review before issuance.
Investor calls. Have the commercial team and IR reviewed earnings call scripts and Q&A guidance for references to the patented indication’s patient population?
Sales force training. Do training materials reference clinical outcomes data tied to the patented use? This is the highest-risk category — a training manual is specific, internal, and directly attributable to the company.
Website and promotional materials. Does any promotional material reference the carved-out indication’s label history, clinical data, or patient population without specifically limiting it to the approved use?
Medical information responses. Does the medical affairs function have written guidance on how to respond to unsolicited requests about the patented use?
Post-launch monitoring. Is there a process to track physician-facing statements and review them on a rolling basis for affirmative reference to the patented indication?
THE CASE YOUR LITIGATION COUNSEL NEEDS TO HEAR
For the brand CLO facing a section viii filing, three points that Hikma directly changes:
The complaint must allege specific facts. Market share and commercial success data are insufficient. The complaint needs to identify specific communications — the press release language, the sales call documentation, the training material — that constitute affirmative encouragement of the patented use. A complaint pleaded on information and belief, without those facts, will not survive a motion to dismiss.
Investigation has to start before launch. The filer’s pre-launch investor materials, commercial team communications, and FDA correspondence are not in the public record. A preliminary injunction motion requires the same factual specificity as the complaint. The investigation window is the period between ANDA filing and launch.
The patent-indication map matters as much as the label. If multiple patents cover different aspects of the patented use, the complaint needs to allege inducement of each. A broad inducement theory resting on the full commercial footprint of the branded drug does not survive Hikma if each patent covers a specific method claim.
THREE WORKSTREAMS
IMMEDIATE — Audit Section viii Filings Against Your Patent Portfolio
For any ANDA or 505(b)(2) filing with a section viii carve-out pending or recently resolved: map the ANDA filer’s commercial communications against the Hikma standard now, before the next earnings cycle adds new investor materials to the record. The analysis should cover investor presentations, the company website, and any commercial team statements attributable to the filer’s sales organization.
BUSINESS IMPACT: Section viii filers that have already launched are building a commercial record. The older the launch, the harder it is to plead specific inducement facts that post-date the Twombly standard. The audit clock starts at filing, not at launch.
NEAR-TERM — Train the Commercial Team on Section viii Boundaries
For the CLO overseeing a generic or biosimilar launch: draft guidance for commercial, medical affairs, and IR covering what the Hikma standard protects and what it does not. Address press releases, investor calls, medical information responses, and sales force training materials as separate categories — each has a different risk profile and a different review owner.
BUSINESS IMPACT: One investor call reference to a carved-out indication’s patient population, without adequate qualification, creates the specific fact a brand complaint needs. The training gap is the litigation risk.
STRATEGIC — Revisit Your Section viii Label Strategy
The label is the starting point, not the endpoint. If your company has relied on a section viii carve-out for a product already on the market, review whether post-launch commercial communications have created a gap between the carved-out label and the product’s actual commercial positioning. That gap is what a well-pleaded inducement complaint will target.
BUSINESS IMPACT: A legacy launch with inadequate commercial communication controls carries greater exposure than a new launch designed around the Hikma standard. The retrospective audit is the higher-stakes exercise because the communications are already in the market.
“The question is not whether a physician could read these materials as instructions to infringe. The question is whether the defendant actively encouraged infringement through its own statements.”
— Justice Jackson, Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (June 4, 2026)
ABOUT THE AUTHOR
John LaRocca is a New York and New Jersey-barred attorney with 37 years of legal experience, including approximately 26 years as GC or CLO at specialty pharma and biotech companies including Actavis, Eagle Pharmaceuticals, Aerie Pharmaceuticals, and Y-mAbs Therapeutics. His transactions include the Aerie/Alcon acquisition (~$930M) and Y-mAbs/SERB acquisition ($412M, 105% premium). He runs LaRocca Advisory Services, a fractional CLO practice for PE-backed specialty pharma and commercial-stage biotech. Subscribe at laroccaj.substack.com.


